Why the study?
What are the current practices and limitations regarding the use of remote monitoring for cardiovascular implantable electronic devices in Europe?
What are the current practices and limitations regarding the use of remote monitoring for cardiovascular implantable electronic devices in Europe?
Remote monitoring for cardiovascular implantable electronic devices is widely used in Europe (85% of responding centres) and expected to grow, though its development is hindered by legal, reimbursement, and guideline limitations.
Answers are grounded in this paper and cite their sources.
Informs CIED remote monitoring implementation strategies across Europe; leaves open resolution of ethical, legal, and reimbursement barriers through prospective research and guidelines.
This survey sampled today's European practices in the use of remote monitoring (RM) for the follow-up of active cardiovascular implantable electronic devices. Eighty-five per cent of the responding centres are currently using RM. For the majority, RM is expected to increase importantly within 5 years, and it has already led to a new organization of care based on dedicated allied professionals and/or the creation of RM units. There are still major limitations for the development of RM, such as ethical and legal aspects, reimbursement issues, and the lack of specific national- and European-updated guidelines which need to be informed.
No takes yet. Share an insight, caveat, or question.
Halimi et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: